<Anchor>
AstraZeneca vaccination, which is constantly controversial for safety, will resume from today (12th).
However, people under the age of 30 decided to get another vaccine given the risk of blood clots.
This is Jang Se-man.
<Reporter>
To decide whether to continue using the AstraZeneca vaccine, health authorities analyzed the benefits and risks of the vaccine by age group, as did the European Medicines Agency.
It is assumed that the number of confirmed cases per day is up to an average of 1,200 per day for three months, and the entire population has received the AstraZeneca vaccine.
In their 30s, the effect of preventing corona death was 6.9, while the number of deaths from blood clots was predicted to be 4.
It means that the vaccination is more beneficial than the real one.
The same was true for people in their 40s and older, with the higher the age group, the greater the benefit than the risk.
On the other hand, people in their twenties have a greater risk of dying from blood clots than to prevent death.
The health authorities have therefore decided to resume the AstraZeneca vaccination, which had been discontinued for under 60 for four days, from today, but another vaccine for those under 30.
The problem is that there is no vaccine plan for 640,000 people under the age of 30 who will be vaccinated against AstraZeneca in the second quarter.
[Eun-kyung Jung/Chief of the Korea Disease Management Administration: People under the age of 30 have to receive other vaccines, and plans for which vaccines to be given and at what time should be supplemented.]
Even under the age of 30, the first dose of AstraZeneca vaccine is given. Of the 135,000 who finished, those who had no side effects of blood clots were given a second dose of the same vaccine.